

# Correlation of Hematological Toxicity with the Bone Marrow Radiation Dose and Volume during Concurrent Chemo Radiation in Patients with Cervical Cancer

Ragavendra D Sagar

Department of Radiation Oncology, J N Medical College, Belagavi, Karnataka, India.

Irappa Madabhavi

Department of Medical and Pediatric Oncology, Kerudi Cancer Hospital, Bagalkot, J N Medical College, Belagavi, and Nanjappa Hospital, Shimoga, Karnataka, India.

Swaroop Revannasiddaiah

**Aims & Objective:** Hematological toxicity is common in patients with cervical cancer treated with concurrent chemo radiotherapy (CT-RT), so the purpose is to assess this hematological toxicity and correlate the toxicity with the dose and volume of bone marrow included in the field of radiation.

**Materials & Methods:** Twenty five patients with histologically proven cervical cancer attending to our Cancer centre from July 2018-August 2019 were the subjects of this study. Patients were treated on 6 MV linear accelerator with a radical intent with concurrent chemotherapy using cisplatin 50 mg weekly. The planning CT was done for all the patients before the treatment and contouring of the pelvic bone marrow apart from other organs at risk was done. Hematological toxicity was assessed using RTOG common toxicity criteria weekly during and at 2 weeks after the completion of the treatment.

**Results:** A total of 25 patients on CT-RT treatment were assessed. Sixteen patients were in locally advanced stage. The variation in HB, TLC, Platelets, and ANC counts from the baseline to 2 weeks after chemo radiotherapy were assessed. Grade II anemia was observed in 12 and Grade III in 2 patients. There were no toxicity as far as WBC and platelets were considered. There was also no correlation between the volume of bone marrow included in the field of irradiation and appearance of anemia.

**Conclusion:** CT-RT for cervical cancer is safe and is associated with minimal hematological toxicity in the form of anemia. The toxicity is same for different volumes of bone marrow included in the field of irradiation with both 3DCRT as well as IMRT technique. The toxicity observed is probably contributed by Cisplatin.

## Introduction

Cervical cancer is the second most common cancer worldwide among women next to breast cancer and is the primary cause of cancer related deaths in developing countries. Each year cervical cancer is diagnosed in about 5,00,000 women globally and is responsible for 2,60,000 deaths annually [1].

Approximately one fourth of the world cases of cervical cancer detected each year in India and the highest incidence is seen in Chennai, lowest in Delhi and the incidence in Bangalore is 21.7/lakh. In our department, cervical cancer formed 18.39% of total cases of cancers from 1998-2005 [2].

Most of the patients are diagnosed in locally advanced stage for which concurrent chemo radiation is the treatment of choice which is followed by brachytherapy. Concurrent chemotherapy and radiation became the standard of care for cervical cancer since 1999-2000. National cancer

institute made a clinical announcement stating that cisplatin based chemotherapy is the new standard of therapy for cervical cancer. This NCI alert came on 23 February, 1999 showed that platinum based chemotherapy used along with radiation had twelve percent increase in local control/survival [3].

Cisplatin chemotherapy is known for its severe hematological toxicity. Pelvic radiation adds to this and is related to the extent of bone marrow that is involved in the field of radiation. The combined toxicity when severe, leads to interruption in treatment and any delay in completion of planned treatment is associated with a reduced probability of local control in patients receiving curative treatment. Several studies have suggested that there may be as much as 1% decrease in survival and local control for each extra day of treatment beyond a total treatment time of 55-60 days [4].

The hematological toxicity is assessed weekly once throughout the course of radiation and grading of toxicity is done as per RTOG toxicity criteria version 2. With the availability of CT scan for simulation, tumor as well as critical structures is delineated and the dose received by them can be documented. The volume and dose of bone marrow could be correlated with the weekly blood picture values for a better understanding. The pattern of hematological toxicity would probably help us in framing new guidelines for their prevention and early intervention. There are many studies available with sophisticated technology like IMRT with pelvic irradiation; however there is a paucity of literature with conventional techniques as well as 3DCRT. Hence the need for this study.

## **Aims and Objectives**

1. To assess the hematological toxicity during concurrent chemo radiation in patients with cervical cancer.
2. To correlate hematological toxicity with the dose and volume of bone marrow included in the field of radiation.

## **Materials and Methods**

### **Methods of collection of data**

The study is conducted on histological proven cases of cervical cancer attending the department of Radiation oncology at Kerudi Cancer Hospital, Bagalkot, Karnataka, India.

### **Sample Size**

The sample size has been estimated in consultation with a biostatistician based on previous year case load and the sample size is 25.

### **Inclusion criteria**

All patients histologically diagnosed as cervical cancer.

Age: 25-65 years.

KPS  $\geq$  70.

Hemoglobin level  $\geq 10\text{gm}\%$ .

Platelets count  $\geq 1$  lakh.

Total leukocyte count  $\geq 4000/\text{cumm}$ .

## Exclusion criteria

Previous radiation or chemotherapy. Concomitant malignancy.

## Methods

Patients with histologically proven cervical cancer are treated on 6MV linear accelerator with a Radical intent with concurrent chemotherapy using cisplatin (50 mg) weekly. The planning CT was done for all the patients before the treatment and contouring the pelvic bone marrow (ilium, ischium, pubis, sacrum), lumbar spine from L5- ischial tubersoities and proximal femora extending from superior border of femoral heads to the inferior border of ischial tuberosity (Plate 1) apart from other organs at risk like Rectum, Bladder etc were done. Evaluation of plan included the documentation of bone marrow included in the field of irradiation and dose received to it. Hematological toxicity was assessed on weekly basis by recording the HB, Neutrophil, Lymphocyte, ANC and Platelets using RTOG common toxicity criteria version 2 (Table 1).

| Parameters                  | Grade 1       | Grade 2      | Grade3       | Grade4 |
|-----------------------------|---------------|--------------|--------------|--------|
| TLC (1000/ $\mu\text{l}$ ): | 3000-<4000    | 2000-<3000   | 1000<2000    | <1000  |
| ANC (1000/ $\mu\text{l}$ ): | 1500-<1900    | 1000-<1500   | 500-<1000    | 500    |
| HB (gm/dl):                 | 9.5-11        | 7.5-<9.5     | 5-<7.5       | <5     |
| PLT (1000/ $\mu\text{l}$ ): | 75000-<100000 | 50000-<75000 | 25000-<50000 | <25000 |

**Table 1. Showing RTOG Common Toxicity Criteria Version 2.**

At the occurrence of grade III toxicity the treatment in the form of Blood transfusion, Granulocyte monocyte colony stimulating factors and giving gap in the treatment were considered. The patients were assessed throughout the entire duration of treatment and the last assessment was done two weeks after irradiation.

## Statistical Methods

Descriptive statistical analysis has been carried out in the present study. Results on continuous measurements are presented on Mean SD (Min-Max) and results on categorical measurements are presented in Number (%). Significance is assessed at 5% level of significance. Analysis of covariance of toxic levels for adjusting the maximum dose, between two groups of treatment measured, Analysis of variance has been used to find the significance changes in toxic levels at different levels of volume of dose for different time periods.

## Significant figures

+ Suggestive significance (P value:  $0.05 < P < 0.10$ )

\* Moderately significant (P value:  $0.01 < P \leq 0.05$ )

\*\* Strongly significant (P value:  $P \leq 0.01$ )

## Statistical software

The Statistical software namely SAS 9.2, SPSS 15.0, Stata 10.1, MedCalc 9.0.1 and Systat 12.0 were used for the analysis of the data and Microsoft word and Excel have been used to generate graphs (Table 2, 3, 4 and 5).

|                       |                | Unadjusted for<br>maximum dose |         |                | Adjusted for<br>maximum dose |         |
|-----------------------|----------------|--------------------------------|---------|----------------|------------------------------|---------|
|                       | Conventional   | 3DCRT                          | P value | Conventional   | 3DCRT                        | P value |
| Hemoglobin<br>(gm/dl) |                |                                |         |                |                              |         |
| Before RT             | 11.64±0.29     | 11.59±0.44                     | 0.919   | 11.59±0.33     | 11.66±0.37                   | 0.9     |
| Week I                | 11.89±0.33     | 11.45±0.51                     | 0.449   | 11.87±0.39     | 11.47±0.45                   | 0.51    |
| Week II               | 11.43±0.3      | 10.59±0.55                     | 0.168   | 11.36±0.38     | 10.67±0.43                   | 0.246   |
| Week III              | 11.14±0.36     | 10.79±0.48                     | 0.564   | 11.07±0.38     | 10.87±0.43                   | 0.738   |
| Week IV               | 10.55±0.3      | 10.68±0.3                      | 0.76    | 10.49±0.27     | 10.75±0.31                   | 0.533   |
| Week V                | 10.28±0.34     | 10.05±0.34                     | 0.639   | 10.21±0.31     | 10.13±0.35                   | 0.867   |
| After RT              | 10.8±0.23      | 10.61±0.42                     | 0.68    | 10.73±0.28     | 10.69±0.32                   | 0.93    |
| Platelet count        |                |                                |         |                |                              |         |
| Before RT             | 3.70±0.29      | 3.44±0.46                      | 0.63    | 3.67±0.35      | 3.47±0.40                    | 0.712   |
| Week I                | 3.72±0.32      | 3.12±0.27                      | 0.181   | 3.72±0.29      | 3.12±0.33                    | 0.199   |
| Week II               | 2.82±0.24      | 2.56±0.28                      | 0.497   | 2.81±0.25      | 2.58±0.28                    | 0.55    |
| Week III              | 2.51±0.23      | 2.43±0.15                      | 0.782   | 2.51±0.20      | 2.43±0.23                    | 0.794   |
| Week IV               | 2.38±0.22      | 2.18±0.14                      | 0.477   | 2.37±0.19      | 2.19±0.21                    | 0.564   |
| Week V                | 2.29±0.19      | 2.12±0.14                      | 0.509   | 2.27±0.16      | 2.15±0.19                    | 0.634   |
| After RT              | 3.00±0.32      | 2.43±0.17                      | 0.155   | 2.99±0.26      | 2.45±0.29                    | 0.191   |
| Total counts          |                |                                |         |                |                              |         |
| Before RT             | 8728.57±871.48 | 8918.18±668.49                 | 0.87    | 8645.34±767.78 | 9024.12±867.59               | 0.748   |
| Week I                | 6139.50±456.31 | 6726.36±687.72                 | 0.469   | 6152.97±542.96 | 6709.22±613.55               | 0.507   |
| Week II               | 5655.71±537.19 | 6330.91±750.43                 | 0.46    | 5668.51±612.81 | 6314.63±692.47               | 0.495   |
| Week III              | 4485.00±475.26 | 5693.64±639.66                 | 0.135   | 4465.17±530.57 | 5718.87±599.54               | 0.134   |
| Week IV               | 4901.43±766.29 | 4359.09±421.83                 | 0.571   | 4910.21±644.37 | 4347.91±728.14               | 0.571   |
| Week V                | 4865.71±646.72 | 4369.09±510.43                 | 0.569   | 4887.69±585.23 | 4341.12±661.30               | 0.545   |
| After RT              | 4898.57±673.16 | 5408.18±558.45                 | 0.58    | 4898.27±619.47 | 5408.56±700.01               | 0.593   |
| ANC                   |                |                                |         |                |                              |         |
| Before RT             | 5748.71±616.58 | 6152.36±618.23                 | 0.653   | 8645.34±767.78 | 9024.12±867.59               | 0.748   |
| Week I                | 4378.64±388.04 | 4700.36±638.33                 | 0.657   | 6152.97±542.96 | 6709.22±613.55               | 0.507   |
| Week II               | 4199.14±527.04 | 4689.91±628.64                 | 0.553   | 5668.51±612.81 | 6314.63±692.47               | 0.495   |
| Week III              | 3251.79±411.21 | 4261.45±561.92                 | 0.151   | 4465.17±530.57 | 5718.87±599.54               | 0.134   |
| Week IV               | 3569.64±574.9  | 3192.55±377.32                 | 0.611   | 4910.21±644.37 | 4347.91±728.14               | 0.571   |
| Week V                | 3569.57±576.61 | 3199.73±481.75                 | 0.64    | 4887.69±585.23 | 4341.17±661.30               | 0.545   |
| After RT              | 3205.14±483.62 | 3744.18±493.5                  | 0.449   | 4898.27±619.47 | 5408.58±700.05               | 0.593   |

**Table 2. Analysis of Estimates of Hemoglobin Levels, Platelet Counts, Total Counts and ANC for Toxicity Levels During the Treatment Period According to Conventional or 3DCRT with and without Adjusting for Maximum Dose.**

|           | Hemoglobin | Platelet count | Total count     | ANC             | LYM            |
|-----------|------------|----------------|-----------------|-----------------|----------------|
| Before RT | 11.62±1.22 | 3.58±1.28      | 8812±2795.85    | 5926.32±2162.54 | 1957.84±721.14 |
| Week I    | 11.70±1.43 | 3.45±1.09      | 6397.72±1958.35 | 4520.2±1742.41  | 1273.76±592.81 |
| Week II   | 11.06±1.49 | 2.7±0.91       | 5952.8±2210.53  | 4415.08±1994.87 | 883.72±404.18  |
| Week III  | 10.98±1.44 | 2.47±0.72      | 5016.8±1990.76  | 3696.04±1729.49 | 754.76±479.48  |

|          |            |           |                |                 |                |
|----------|------------|-----------|----------------|-----------------|----------------|
| Week IV  | 10.61±1.04 | 2.29±0.69 | 4662.8±2311.7  | 3403.72±1787.57 | 682.80±265.00  |
| Week V   | 10.18±1.2  | 2.22±0.61 | 4647.2±2104.56 | 3406.84±1902.66 | 711.76±423.86  |
| After RT | 10.72±1.11 | 2.75±0.98 | 5122.8±2220.9  | 3442.32±1721.77 | 1168.44±690.64 |
| P value  | <0.001**   | <0.001**  | <0.001**       | <0.001**        | <0.001**       |

**Table 3. Estimates of Toxicity based on Hemoglobin, Platelet counts, Total count, ANC and Lymphocyte.**

|      |         |           |            | Mean Changes<br>of hemoglobin<br>from baseline |            |           |          |
|------|---------|-----------|------------|--|------------|-----------|----------|
| Dose |         | At Week I | At Week II | At Week III                                    | At week IV | At week V | After RT |
| V4   | <200    | -         | -          | -  | -          | -         | -        |
|      | 201-300 | 0.7       | 1.05       | 1  | 0.43       | 1.1       | 0.1      |
|      | >300    | -0.22     | 0.47       | 0.57   | 1.12       | 1.51      | 1.06     |
|      | P value | 0.106     | 0.368      | 0.485  | 0.186      | 0.516     | 0.242    |
| V10  | <200    | -         | -          | -  | -          | -         | -        |
|      | 201-300 | 0.56      | 0.88       | 0.82   | 0.84       | 1.42      | 0.68     |
|      | >300    | -0.24     | 0.48       | 0.59   | 1.06       | 1.45      | 0.96     |
|      | P value | 0.131     | 0.502      | 0.687  | 0.662      | 0.959     | 0.713    |
| V20  | <200    | 0.5       | 1.5        | 1.2  | 1.6        | 2.7       | 0.4      |
|      | 201-300 | 0.58      | 0.73       | 0.73   | 0.65       | 1.1       | 0.75     |
|      | >300    | -0.24     | 0.48       | 0.59   | 1.06       | 1.45      | 0.96     |
|      | P value | 0.327     | 0.678      | 0.863  | 0.628      | 0.462     | 0.917    |
| V30  | <200    | 0.13      | 0.76       | 0.59   | 0.54       | 1.05      | -0.1     |
|      | 201-300 | -0.42     | 0.43       | 0.67   | 1.19       | 1.97      | 1.61     |
|      | >300    | 0.2       | 0.42       | 0.66   | 1.6        | 1.18      | 1.5      |
|      | P value | 0.419     | 0.795      | 0.987  | 0.092+     | 0.159     | 0.014*   |
| V40  | <200    | 0.02      | 0.63       | 0.69   | 0.85       | 1.32      | 0.71     |
|      | 201-300 | -0.25     | 0.45       | 0.87   | 1.5        | 2.07      | 1.55     |
|      | >300    | -0.35     | 0.3        | -0.55  | 0.9        | 0.65      | 0.6      |
|      | P value | 0.816     | 0.906      | 0.283  | 0.372      | 0.224     | 0.485    |
| V4   | <200    | -         | -          | -  | -          | -         | -        |
|      | 201-300 | -0.17     | 0.79       | 1.34   | 1.48       | 1.71      | 1.04     |
|      | >300    | 0.19      | 0.9        | 1.06   | 1.26       | 1.3       | 0.79     |
|      | P value | 0.551     | 0.853      | 0.673  | 0.73       | 0.491     | 0.761    |
| V10  | <200    | -         | -          | -  | -          | -         | -        |
|      | 201-300 | -0.12     | 0.7        | 1.14   | 1.37       | 1.57      | 0.85     |
|      | >300    | 0.19      | 0.92       | 1.1  | 1.27       | 1.32      | 0.83     |
|      | P value | 0.576     | 0.661      | 0.951  | 0.866      | 0.645     | 0.978    |
| V20  | <200    | -1.61     | -0.57      | 0.37   | 0.94       | 1.26      | -0.35    |
|      | 201-300 | 0.26      | 1.01       | 1.33   | 1.48       | 1.64      | 1.15     |
|      | >300    | 0.19      | 0.92       | 1.1  | 1.27       | 1.32      | 0.83     |
|      | P value | 0.261     | 0.351      | 0.779  | 0.906      | 0.859     | 0.664    |
| V30  | <200    | 0.34      | 1.17       | 1.63   | 1.7        | 1.81      | 1.55     |
|      | 201-300 | 0.05      | 0.65       | 0.67   | 0.82       | 0.84      | 0.4      |
|      | >300    | -0.14     | 0.75       | 0.93   | 1.42       | 1.52      | 0.26     |
|      | P value | 0.698     | 0.509      | 0.178  | 0.208      | 0.113     | 0.121    |
| V40  | <200    | 0.26      | 0.88       | 1.15   | 1.24       | 1.34      | 0.91     |
|      | 201-300 | -0.1      | 0.97       | 0.95   | 1.15       | 1.18      | 0.89     |
|      | >300    | -0.28     | 0.54       | 1.2  | 2.17       | 2.11      | -0.02    |
|      | P value | 0.691     | 0.879      | 0.932  | 0.529      | 0.57      | 0.698    |
| V4   | <200    | -         | -          | -  | -          | -         | -        |
|      | 201-300 | 1327      | 1666.25    | 1730.5   | 2664.75    | 1898      | 2342.75  |
|      | >300    | 1421.19   | 1481.71    | 2325.48  | 2495.52    | 2637.86   | 2510.9   |
|      | P value | 0.946     | 0.907      | 0.703  | 0.911      | 0.672     | 0.902    |

|     |         |        |         |         |         |         |        |
|-----|---------|--------|---------|---------|---------|---------|--------|
| V10 | <200    | -      | -       | -       | -       | -       | -      |
|     | 201-300 | 1047   | 1335.6  | 1098.4  | 2358.8  | 1696.8  | 1795.2 |
|     | >300    | 1495.9 | 1555.15 | 2513.25 | 2563.55 | 2725.15 | 2656.2 |
|     | P value | 0.724  | 0.88    | 0.318   | 0.882   | 0.52    | 0.488  |
| V4  | <200    | -      | -       | -       | -       | -       | -      |
|     | 201-300 | 0.7    | 1.05    | 1       | 0.43    | 1.1     | 0.1    |
|     | >300    | -0.22  | 0.47    | 0.57    | 1.12    | 1.51    | 1.06   |
|     | P value | 0.106  | 0.368   | 0.485   | 0.186   | 0.516   | 0.242  |
| V10 | <200    | -      | -       | -       | -       | -       | -      |
|     | 201-300 | 0.56   | 0.88    | 0.82    | 0.84    | 1.42    | 0.68   |
|     | >300    | -0.24  | 0.48    | 0.59    | 1.06    | 1.45    | 0.96   |
|     | P value | 0.131  | 0.502   | 0.687   | 0.662   | 0.959   | 0.713  |
| V20 | <200    | 0.5    | 1.5     | 1.2     | 1.6     | 2.7     | 0.4    |
|     | 201-300 | 0.58   | 0.73    | 0.73    | 0.65    | 1.1     | 0.75   |
|     | >300    | -0.24  | 0.48    | 0.59    | 1.06    | 1.45    | 0.96   |
|     | P value | 0.327  | 0.678   | 0.863   | 0.628   | 0.462   | 0.917  |
| V30 | <200    | 0.13   | 0.76    | 0.59    | 0.54    | 1.05    | -0.1   |
|     | 201-300 | -0.42  | 0.43    | 0.67    | 1.19    | 1.97    | 1.61   |
|     | >300    | 0.2    | 0.42    | 0.66    | 1.6     | 1.18    | 1.5    |
|     | P value | 0.419  | 0.795   | 0.987   | 0.092+  | 0.159   | 0.014* |
| V40 | <200    | 0.02   | 0.63    | 0.69    | 0.85    | 1.32    | 0.71   |
|     | 201-300 | -0.25  | 0.45    | 0.87    | 1.5     | 2.07    | 1.55   |
|     | >300    | -0.35  | 0.3     | -0.55   | 0.9     | 0.65    | 0.6    |
|     | P value | 0.816  | 0.906   | 0.283   | 0.372   | 0.224   | 0.485  |
| V4  | <200    | -      | -       | -       | -       | -       | -      |
|     | 201-300 | -0.17  | 0.79    | 1.34    | 1.48    | 1.71    | 1.04   |
|     | >300    | 0.19   | 0.9     | 1.06    | 1.26    | 1.3     | 0.79   |
|     | P value | 0.551  | 0.853   | 0.673   | 0.73    | 0.491   | 0.761  |
| V10 | <200    | -      | -       | -       | -       | -       | -      |
|     | 201-300 | -0.12  | 0.7     | 1.14    | 1.37    | 1.57    | 0.85   |
|     | >300    | 0.19   | 0.92    | 1.1     | 1.27    | 1.32    | 0.83   |
|     | P value | 0.576  | 0.661   | 0.951   | 0.866   | 0.645   | 0.978  |

**Table 4. Evaluation of Toxicity in Relation to Volume at Different Dose Over the Period of Treatment.**

| Toxicity level | V4          | V10         | V20         | V30         | V40         |
|----------------|-------------|-------------|-------------|-------------|-------------|
| Week1          |             |             |             |             |             |
| · GrI          | 94.71±6.21  | 89.56±7.64  | 80.81±10.70 | 46.14±15.46 | 29.35±15.89 |
| Week2          |             |             |             |             |             |
| · GrI          | 96.36±4.04  | 92.13±6.12  | 84.84±10.92 | 56.27±9.95  | 38.69±12.74 |
| · GrII         | 90.08±10.99 | 83.62±11.59 | 75.89±12.92 | 24.94±6.22  | 9.97±4.35   |
| Week3          |             |             |             |             |             |
| · GrI          | 93.22±6.49  | 86.26±8.18  | 78.82±10.51 | 43.02±14.90 | 26.51±12.19 |
| · GrII         | 93.87±4.61  | 89.46±8.24  | 82.42±12.86 | 48.26±18.39 | 33.74±18.58 |
| Week4          |             |             |             |             |             |
| · GrI          | 92.22±4.62  | 84.84±6.57  | 77.30±8.45  | 48.54±18.41 | 36.20±20.64 |
| · GrII         | 100.00±0.00 | 100.00±0.00 | 100.00±0.00 | 72.71±14.80 | 52.28±17.96 |
| Week5          |             |             |             |             |             |
| · GrI          | 93.16±5.47  | 86.39±7.15  | 78.79±8.59  | 48.21±17.14 | 32.44±18.06 |
| · GrII         | 97.28±3.14  | 93.06±7.15  | 89.35±8.59  | 51.95±16.34 | 35.19±16.02 |
| · GrIII        | 94.09       | 85          | 81.38       | 65          | 62.5        |
| After RT       |             |             |             |             |             |
| · GrI          | 95.26±5.27  | 89.61±7.96  | 83.49±11.99 | 56.59±16.74 | 38.61±14.02 |
| · GrII         | 97.96±3.46  | 92.62±9.71  | 86.56±13.91 | 53.11±15.50 | 35.09±19.26 |

|       |      |       |       |       |       |
|-------|------|-------|-------|-------|-------|
| GrIII | 91.1 | 88.79 | 72.06 | 41.09 | 25.97 |
|-------|------|-------|-------|-------|-------|

**Table 5. Evaluation of Volume/Dose According to Toxicity (Grades) in Weeks.**

## Results

A prospective clinical study consisting of 25 patients histopathologically proven cervical cancer is done to assess the hematological toxicity during concurrent chemo radiation in patients with cervical cancer and to correlate the hematological toxicity with the dose and volume of bone marrow included in the field of radiation is attempted.

Age group of patients ranged from 38-81 yrs with a mean of 54 yrs.

Most of the patients were in the early stage with stage IIB accounting for 48 % (12) of 25 patients. One patient had Stage IB, four had Stage IIIB, six were treated with Post Operative intent and two had Vault recurrence (Table 6).

| Age in years                               | Number of patients | %     |
|--|--------------------|-------|
| 31-40                                      | 3                  | 12    |
| 41-50                                      | 8                  | 32    |
| 51-60                                      | 7                  | 28    |
| >60  | 7                  | 28    |
| Total                                      | 25                 | 100   |
| ( Mean $\pm$ SD: 53.72 $\pm$ 11.56)        |                    |       |
| Diagnosis                                  | (n=25)             |       |
| Cancer cervix                              |                    |       |
| · Stage IB                                 | 1                  | 4     |
| · Stage IIB                                | 12                 | 48    |
| · Stage IIIB                               | 4                  | 20    |
| CA. Cervix Post Op                         | 6                  | 16    |
| VAULT recurrence                           | 2                  | 8     |
| Treatment                                  | (n=25)             |       |
| Conventional                               | 14                 | 56    |
| 3D CRT                                     | 11                 | 44    |
| Chemotherapy cycles                        | (n=25)             |       |
| 3  | 2                  | 8     |
| 4  | 10                 | 40    |
| 5  | 13                 | 52    |
| Corner Shielding in conventional technique | (n=14)             |       |
| No   | 11                 | 78.57 |
| Yes  | 3                  | 21.42 |
| Blood transfusion                          | (n=25)             |       |
| No   | 19                 | 76    |
| Yes  | 6                  | 24    |
| Gap in chemotherapy day                    | (n=25)             |       |
| No   | 13                 | 56    |
| Yes  | 12                 | 48    |

**Table 6. Age distribution, Stage wise Distribution, Treatment Received, Chemotherapy Cycles, Corner Shielding in Conventional Technique, Blood Transfusion, Gap in Chemotherapy (1-4 days).**

All patients received radiation dose ranging from 4500 to 5040 cGy over 25 to 28 fractions with

concurrent weekly chemotherapy of cisplatin 50 mg.

Fourteen patients underwent conventional technique and 11 with 3DCRT technique. All patients received radiation without any gap.

Hematological toxicity in the form of Anaemia ie Grade I was seen in 19 patients, Grade II in 12 patients and Grade III in 2 patients.

Eight patients had Grade I at 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> weeks, 11 patients in 4<sup>th</sup> week and 13 patients in the 5<sup>th</sup> week. However at 2 weeks after treatment only 7 patients continued to have Grade I. Grade II anemia was observed from 2<sup>nd</sup> week onwards and persisted in 3 patients at 2 weeks after treatment. Grade III was observed in 1 patient at 5<sup>th</sup> week and in another patient at 2 weeks after treatment (Figure 1).

**Figure 1. Showing the Graphical Representation of the Hemoglobin Levels During the Treatment Period.**

Seven patients received blood transfusion. Among them one patient had Grade III, one had Grade II anemia during 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> week of treatment. The remaining three received blood transfusion before the commencement of RT.

Twelve patients had gap in chemotherapy it ranged from 2-4 days. The reason for the gap were grade III anemia in one and rest of them had gastrointestinal toxicity in the form of vomiting, loose stools etc.

Thirteen patients received 5 cycles of chemotherapy, 10 patients received 4 and 2 received only 3 cycles. The reason for only 3 cycles was acute enteritis.

None of the patients encountered WBC or Platelets toxicity.

Though the mean difference is large at different levels of volume, the significant is not achieved is just because of sample size (sample size distribution at each level of volume is uneven and small), the results give evidence of trend about the how the toxicity changes at different levels of volume for dose range and each time. P value are not very much important, only mean changes is important to measure trend the relationship, to measures changes in toxic levels at different levels of volume, at different dose across the different time periods.

## Discussion

A prospective clinical study consisting of 25 patient's of histopathologically proven cervical cancer is included to assess the hematological toxicity during concurrent chemo radiation in patients with cervical cancer and to Correlate this hematological toxicity with the dose and volume of bone marrow included in the field of radiation.

Age group of patients ranged from 38-81 yrs with a mean of 54 yrs. According to various other authors the mean age were ranging from 37-52 yrs [5]. Most of the patients in our study were in the early stage with stage IIB accounting for major of 48% (12) of 25 patients and a similar occurrence of 45% is noted as per different authors [6].

All patients received radiation dose ranging from 4500 to 5040 cGy over 25 to 28 fractions with concurrent weekly chemotherapy of cisplatin 50mg. Similar studies done by authors used RT dose varying from 4300 -5000 cGy over 25-28 fractions but chemotherapy dose of 40mg/m<sup>2</sup> of cisplatin was used [7].



Hematological toxicity in the form of anemia was noted in 80% of our patients. Grade I was noted in 19 (95%) patients, Grade II in 12 (60%) patients and Grade III-2 (10%) patients at various points of time during treatment. Among the patients who developed Grade III toxicity, one patient was in the 5<sup>th</sup> week of CTRT and hence the 5<sup>th</sup> cycle of cisplatin was withheld while the second patient developed at 2 weeks following CTRT. Others authors Bhavaraju et al noted anemia in 62.9% overall, Grade I in 51.1% and Grade II in 11.4% of patients, Grade III, IV were not present [6]. Singh et al noted the similar Grade I, II in 75% and 55% and in study by Shibita et al. [8] Grade III, IV in 50% and 14% higher toxicity is because of 70 mg/m<sup>2</sup> of cisplatin dose along with 5-FU. Aich et al noted Grade 0 in none and Grade I, II, III in 54%, 18% and 6% respectively [7]. Rose et al noted Grade I, II, III, IV in 7%, 15%, 5%, 2% patients with concurrent chemo radiation with cisplatin dose of 40mg/m<sup>2</sup> [1]. In GOG study by Keys et al noted Grade 0, I, II, III, IV in 80%, 0.9%, 0.8%, 0.16% and 0% respectively [9]. In study by Peters ET al in SWOG trial, CT with cisplatin 70mg/m<sup>2</sup> with 5FU Grades I, II, III and IV anemia in RT+CT were 23%, 22%, 0.2% and 0% [10]. None of the patients in our study had thrombocytopenia. However Bhavaraju et al did observe Grade 0, I, II and III toxicity in 82.9%, 14.3%, 2.8% and 0 patients respectively [6]. Aich et al grade 0 in 36% and Grade I, II, III in 55%, 9% and 0% respectively [7]. Rose et al noted Grade 0, I, II, III, IV in 44%, 0.8%, 0.2%, 0.1% and 0% of patients respectively [1]. Peters et al noted Grades I, II, III, IV thrombocytopenia in 22%, 0.18, 0.08% and 0% respectively [10].

None of the patients in our study had TLC toxicity. In a study by Bhavaraju et al 28 leucopenia noted with Grade I in 20% and Grade II 31.4% [6]. Aich et al Grade 0 in 44% and Grade I, II, III in 33%, 16% and 7% respectively [7]. Rose et al noted Grade 0, I, II, III, IV in 19%, 0.9%, 14%, 11%, 0.16% patients [1]. Peters et al noted Grades I, II, III, IV leucopenia in 13%, 38%, 32% and 0.02% respectively [10].

None of the patients in our study had ANC toxicity. However in the study by Bhavaraju et al an overall of 51.4% had fall in ANC counts with Grade 0, I, II and III were found to be in 48.6%, 20%, 31.4% and 0% patients respectively [6].

Twelve patients had a gap in chemotherapy the gap ranged from 2-4 days. 11 patients had HT and one patient had severe vomiting and burning micturition. In other studies Abu-Rustum 29.2% of patients had incomplete chemotherapy, 13% due to Hematological toxicity [11]. In study by Bhavaraju et al interruptions in chemo radiotherapy for a period of 1-4 days was observed in 57% patients for the reason of lack of transportation and the patient being unwell and sick [6]. Aich et al treatment in general was delayed by a week due to HT during CTRT [7].

In our study thirteen (52%) patients received 5 cycles of chemotherapy, 10 (40%) patients received 4 cycles of chemotherapy and 2 (0.08%) patients received 3 cycles. Among the patients who received only 3 cycles, one patient developed jaundice the cause of which was not known and the other lady had severe vomiting and so the remaining chemotherapy was not contemplated. In the study by Abu-Rustum et al 10.8% of patients received six cycles of cisplatin but majority (60%) received planned five courses of cisplatin. Serkies et al noted 55% did not receive the planned five cycles of cisplatin due to treatment related hematological toxicity (31%) and non compliance due to delayed first cycle administration or omission of a cycle for reason other than toxicity [12].

Myrna et al only 67% of patients receive the six planned courses of weekly cisplatin. Keys et al one (0.55%) patient received 2 cycles and all other (99.45%) received 4-6 cycles of chemotherapy. Rose et al 0.6%, 1.1%, 1.1%, 4%, 10.2%, 33.5%, 49.4% patients received 1, 2, 3, 4, 5 and >6 cycles of cisplatin chemotherapy respectively [13].

Fourteen patients underwent conventional technique and 11 with 3DCRT technique and there was no significant difference in the toxicities as far as these techniques were considered and there are no studies comparing the toxicities associated with these techniques however in a study by Loren et al BMS-IMRT were compared to conventional (Four field and AP/PA technique) and a significant bone marrow was spared thereby preventing HT [5].

In our study, anemia was observed also in patients who had corner shielding, however it was not statistically significant. None of the available studies have used corner shielding for preventing the HT. Mitchell et al have used customized shielding for pelvic RT, however the associated toxicities have not been documented corner shielding with custom blocks or MLC were mainly used to reduce enteritis [14]. The various volumes of bone marrow were compared with those of other authors and is as shown in the Table below: (Table 7).

| Dose received by bone marrow volume | Four-field box (Our study) (%) | AP/PA plan (Loren) [5] (%) | Four-field box (Loren) [5] (%) | IMRT(Roeske) [15] (%) | IMRT- BMS(Loren 68) (%) |
|-------------------------------------|--------------------------------|----------------------------|--------------------------------|-----------------------|-------------------------|
| V4                                  | 91.2                           | 72.4                       | 99.6                           | 100                   | 90.4                    |
| V10                                 | 89.3                           | 66.9                       | 97.3                           | 100                   | 76.5                    |
| V20                                 | 83.4                           | 62.9                       | 92.7                           | 96                    | 57.5                    |
| V30                                 | 54.8                           | 59.1                       | 59.9                           | 76                    | 46.1                    |
| V40                                 | 40.1                           | 54.1                       | 48.9                           | 49                    | 33.7                    |

**Table 7. Showing Various Bone Marrow Volumes According to the Radiation Techniques.**

Our observations are: 1) V4,V10,V20 Gy is least in AP/PA plan because of only two fields with majority of the bone marrow being outside the field of radiation. 2) All the volume are lesser in the four-field than IMRT because in IMRT multiple fields are used, so in low dose region especially, more of bone marrow volume is receiving greater radiation dose than in four-field box technique. 3) In IMRT-BMS bone marrow can be set as a constraint and then reduction in volume can be accomplished (Table 8).

| Percentage of bone marrow receiving RT dose | Range in percentage | Mean in percentage |
|---|---------------------|--------------------|
| 4 Gy  | 82.31-100           | 91.2               |
| 10 Gy                                       | 78.54-100           | 89.3               |
| 20 Gy                                       | 66.76-100           | 83.4               |
| 30 Gy                                       | 20.54-88.87         | 54.8               |
| 40 Gy                                       | 6.89-73.35          | 40.1               |

**Table 8. Percentage of Bone Marrow Receiving Various Doses.**

Regarding the toxicities that we observed in our study Grade II Anaemia in 12 and Grade III in 2 patients is probably attributed to cisplatin chemotherapy as it did not correlate with the bone marrow volume in the field of irradiation. Using statistical methods, an effort was made to analyze the hematological toxicity adjusting for that week's maximum dose the same was analysed without adjusting the maximum dose. This was done because not only the volume was different for different patients but also the dose received on the day of assessing the toxicity was different. However we did not observe any difference between the two groups.

We did have certain limitations in our study. The sample size is very small and hence further studies enrolling a large number of patients are required to see if the same results can be duplicated. We have used a flat dose of 50 mg Cisplatin and not the recommended which is 40 mg/m<sup>2</sup>. Our last assessment of toxicity was at two weeks after completion of treatment and hence it is difficult to comment on the delayed hematological toxicity that is observed with cisplatin. Bone marrow contouring was done entirely from lumbosacral junction (L5) to ischial tuberosity. Contouring different regions like ileum, ischium, and pubis separately will probably help us to understand the toxicity profile better.

In conclusion, concurrent chemo radiation for cervical cancer is safe, can be completed as scheduled and is associated with minimal hematological toxicity in the form of anemia and no

leucopenia or thrombocytopenia. Chemo radiation induced anemia requiring blood transfusion is uncommon. The volume of bone marrow in the field of irradiation does not correlate with the clinical occurrence of acute hematological toxicity as far as IMRT/3DCRT techniques are considered. Minimal toxicity associated, is probably contributed by concurrent cisplatin administration.

### Summary

A total of 25 patients, undergoing concurrent chemo radiation for cervical cancer were assessed weekly once and at two weeks after treatment for hematological toxicity. An effort was made to correlate the volume of bone marrow included in the field of irradiation as well as the dose received by it to the occurrence of anemia, leucopenia and thrombocytopenia. 80% of patients in the study had changes in hemoglobin levels including all the grades. Anaemia of Grade I was seen in 95%, Grade II in 60% and Grade III in 10% of cases at various times during treatment. Grade IV anemia was not observed. No changes in the ANC, Platelets and TLC were noted. The hemoglobin toxicity when compared to the dose and volume in the field of irradiation was not correlating and probably is attributed to cisplatin chemotherapy rather than radiation.

## Acknowledgements

### Conflicts of Interest

Abstract has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Radiation Science and Medicine on March 2-3, 2021.

### Author Contributions

1. IM, RS conceived and designed the experiment, made critical revisions, and approved the final version. RS and IM analyzed the data and wrote the first draft of the manuscript. RS and IM contributed to the writing of the manuscript. RS and IM agree with the manuscript results and conclusions. IM and RS jointly developed the structure and arguments for the paper. All authors reviewed and approved the final manuscript.

## References

## References

1. Rose Peter G., Bundy Brian N., Watkins Edwin B., Thigpen J. Tate, Deppe Gunther, Maiman Mitchell A., Clarke-Pearson Daniel L., Insalaco Sam. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. *New England Journal of Medicine*. 1999; 340(15)[DOI](#)
2. Arulponni T. R., Janaki M. G., Nirmala S., Ramesh B. S., Rishi K. S., Kirthi K.. Carcinoma cervix treated with Radiotherapy — our experience with emphasis on our concerns. *The Journal of Obstetrics and Gynecology of India*. 2010; 60(1)[DOI](#)
3. Thomas Gillian M.. Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy. *New England Journal of Medicine*. 1999; 340(15)[DOI](#)
4. Mac Manus Michael, Lamborn Kathleen, Khan Waqqar, Varghese Anna, Graef Lorin, Knox Susan. Radiotherapy-Associated Neutropenia and Thrombocytopenia: Analysis of Risk Factors and Development of a Predictive Model. *Blood*. 1997; 89(7)[DOI](#)
5. Mell Loren K., Tiriyaki Hanifi, Ahn Kang-Hyun, Mundt Arno J., Roeske John C., Aydogan

- Bulent. Dosimetric Comparison of Bone Marrow-Sparing Intensity-Modulated Radiotherapy Versus Conventional Techniques for Treatment of Cervical Cancer. *International Journal of Radiation Oncology\*Biophysics*. 2008; 71(5)[DOI](#)
6. V M K Bhavaraju, N Reed, T Habeshaw, Curran J, Stafford P M, Douple E, et al. Acute toxicity of concomitant treatment of chemo radiation with single agent cisplatin in patients with carcinoma of the cervix. 2004; 17(3):90-97.
7. Aich Ranen, Deb Asit, Chaudhuri, Biswas, Das, Ghosh. Concomitant chemoradiation in locally advanced carcinoma of the cervix. *Journal of Obstetrics and Gynaecology of India*. 2007; 57(2):145-150.
8. Chiara Silvana, Bruzzzone Milena, Merlini Laura, Bruzzi Paolo, Rosso Riccardo, Franzone Paola, Orsatti Marco, Vitale Vito, Foglia Giovanni, Odicino Franco, Ragni Nicola, Rugiati Sergio, Conte Pierfranco. Randomized Study Comparing Chemotherapy Plus Radiotherapy Versus Radiotherapy Alone in FIGO Stage IIB-III Cervical Carcinoma. *American Journal of Clinical Oncology*. 1994; 17(4)[DOI](#)
9. Keys Henry M., Bundy Brian N., Stehman Frederick B., Muderspach Laila I., Chafe Weldon E., Suggs Charles L., Walker Joan L., Gersell Deborah. Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma. *New England Journal of Medicine*. 1999; 340(15)[DOI](#)
10. Peters William A., Liu P.Y., Barrett Rolland J., Stock Richard J., Monk Bradley J., Berek Jonathan S., Souhami Luis, Grigsby Perry, Gordon William, Alberts David S.. Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. *Journal of Clinical Oncology*. 2000; 18(8)[DOI](#)
11. Kumar Lalit, Kaushal R., Nandy M., Biswal B.M., Kumar S., Kriplani A., Singh Rajveer, Rath G.K., Kochupillai V.. Chemotherapy Followed by Radiotherapy versus Radiotherapy Alone in Locally Advanced Cervical Cancer: A Randomized Study. *Gynecologic Oncology*. 1994; 54(3)[DOI](#)
12. Thomas Gillian M.. Improved Treatment for Cervical Cancer — Concurrent Chemotherapy and Radiotherapy. *New England Journal of Medicine*. 1999; 340(15)[DOI](#)
13. Park Tchan Kyu, Lee Sung Ki, Kim Soo Nyung, Hwang Tai Sik, Kim Gwi Eon, Suh Chang Ok, Loh Juhn Kyu. Combined Chemotherapy and Radiation for Bulky Stages I-II Cervical Cancer: Comparison of Concurrent and Sequential Regimens. *Gynecologic Oncology*. 1993; 50(2)[DOI](#)
14. Eifel P J, Mitchell, Winter K, Morris M, Levenback C, Grigsby, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. *J Clin Oncol*. 2004; 1(5):872-880.
15. Roeske J C, Mundt A J, Ishijima S J, Chmura, Stevens SK, Moore SG, et al. Incorporation of magnetic resonance imaging into intensity modulated whole pelvic radiotherapy treatment planning to reduce the volume of pelvic bone marrow irradiated. *Int Congress series*. 2004; 1268:307-312.